Portal Biotech, a London, UK-based biotechnology company providing a platform for researchers, raised $35M in Series A funding.
The round was led by NATO Innovation Fund and Earlybird Venture Capital, with participation from existing investors SCVC, Pillar VC, 8VC, Amino Collective, and Outsized, as well as new investors We Venture Capital, British Business Bank and WS Investment Company.
The company intends to use the funds to accelerate its roadmap, deepen collaborations with pharmaceutical and biotech innovators, and expand its R&D, engineering, and data-science teams.
Led by CEO Andy Heron, Portal Biotech provides a platform that delivers a technology for sequencing intact full-length proteins at the single-molecule level to completely characterise all protein mutations and modifications. Coupled with advanced AI methods, this data gives researchers a detailed view into the complexities of the proteome that traditional technologies cannot match, laying the groundwork for new foundational AI models of the dynamic proteome that will improve the understanding of protein biology and life sciences.
FinSMEs
01/07/2025
